Form 4: Akero Director Sells Shares in Novo Nordisk Merger

Akero Therapeutics director Yuan Xu disposed of all beneficial ownership in the company following its acquisition by Novo Nordisk.

Summary

• Yuan Xu, a director of Akero Therapeutics, Inc. (AKRO), reported the disposal of all beneficial ownership in the company.
• This transaction occurred on December 9, 2025, as a result of the merger of Akero Therapeutics with NN Invest Sub, Inc., a subsidiary of Novo Nordisk A/S.
• Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk A/S.
• The disposal included 9,398 restricted stock units (RSUs) and various stock options.
• Each RSU was converted into $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) worth $6.00 upon achievement of a specified milestone.
• Each stock option was converted into a cash payment equal to the excess of the $54.00 Closing Consideration over the option's exercise price, multiplied by the number of shares, plus one CVR per share.

Sentiment

Score: 7

Explanation: The reporting person received a significant cash payout for their equity holdings, including a fixed cash consideration and potential additional value from CVRs, indicating a favorable outcome from the merger.

Positives

• The reporting person received a cash payout for their equity holdings (RSUs and stock options) as part of the merger.
• The merger provided a fixed cash consideration of $54.00 per share for RSUs.
• The reporting person received contingent value rights (CVRs) potentially worth an additional $6.00 per RSU/option share if a specified milestone is achieved.
• The acquisition by Novo Nordisk A/S provides a clear exit strategy and liquidity for shareholders.

Negatives

• The reporting person no longer holds direct beneficial ownership in Akero Therapeutics, Inc.
• Akero Therapeutics ceases to be an independent publicly traded entity.
• The value of the CVR is contingent on a future milestone, introducing uncertainty regarding the full potential payout.

Risks

• The value of the Contingent Value Right (CVR) is not guaranteed and depends on the achievement of a specified milestone, meaning the $6.00 per CVR may not be realized.

Future Outlook

Akero Therapeutics, Inc. has become a wholly-owned subsidiary of Novo Nordisk A/S following the completion of the merger, indicating its future operations will be integrated within Novo Nordisk's structure.

Industry Context

The acquisition of Akero Therapeutics by Novo Nordisk A/S reflects a broader trend of consolidation in the biopharmaceutical industry, where larger pharmaceutical companies acquire smaller, innovative firms to expand their pipelines and therapeutic areas, particularly in areas like metabolic diseases where Akero has focused.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs for their shares, providing liquidity and a potential upside.
• Employees (with equity): Those holding RSUs and stock options received cash payouts and CVRs, similar to the director.

Next Steps

• Akero Therapeutics is now a wholly-owned subsidiary of Novo Nordisk A/S.
• The Contingent Value Rights (CVRs) will pay out if a specified milestone is achieved.

Key Dates

Keywords

Akero Therapeutics, AKRO, Novo Nordisk, Merger, Acquisition, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Contingent Value Right, CVR, Yuan Xu